New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Sucralose increases hypothalamic activity linked to hunger more than sugar or water, especially in women and people with ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

Novo Nordisk and the Chinese group’s wholly-owned subsidiary The United Bio-Technology have entered into an exclusive license ...

Guangdong, China and Bagsværd, Denmark, 24 March 2025 –The United Laboratories International Holdings Limited (TUL) and Novo ...

While the exact mechanism is unknown, the data suggest a multitude of benefits independent of large weight loss.

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

A large clinical trial, co-led by researchers at the UNC School of Medicine, has shown that the popular weight-loss drug ...

A new study found that a popular zero-calorie sugar substitute disrupts regions of the brain responsible for regulating ...